Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Cardiotoxicity × Immunomodulating Agents × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 2 Heart Diseases 1 Cardiotoxicity 1

Interventions

Echocardiography 13 Doxorubicin 9 Exercise 8 Electrocardiography 7 Trastuzumab 5 Cyclophosphamide 5 Carvedilol 4 Docetaxel 3 Atorvastatin 3 salicylhydroxamic acid 2 sacubitril and valsartan sodium hydrate drug combination 2 empagliflozin 2 Tablets 2 Social Determinants of Health 2 Magnetic Resonance Spectroscopy 2 Ivabradine 2 High-Intensity Interval Training 2 Blood Specimen Collection 2 Bisoprolol 2 Antineoplastic Agents 2 Anthracyclines 2 sulforaphane 1 schizandrin 1 pegfilgrastim 1 nicotinamide-beta-riboside 1 mitoquinone 1 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination 1 epicatechin gallate 1 dapagliflozin 1 candesartan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03530215 2023-04-13

EROCA

Groupe Hospitalier Pitie-Salpetriere

500,000 enrolled

Heart Diseases, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡